辉瑞预计2025年新政府不会对美国疫苗政策做出重大改变-动脉网

Pfizer Does Not Anticipate Material Changes To US Vaccine Policy From The Incoming Administration In 2025

benzinga 等信源发布 2024-12-17 09:05



可切换为仅中文







On Tuesday, Pfizer Inc. PFE released its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion compared to a consensus of $63.28 billion.

周二，辉瑞公司（PfizerInc.）发布了2025年全年财务指导意见，预计收入将在610亿美元至640亿美元之间，而普遍认为收入为632.8亿美元。

For 2025, Pfizer expects revenue from COVID-19 products to remain consistent with 2024, excluding approximately $1.2 billion in one-time Paxlovid revenue recognized in 2024.

2025年，辉瑞预计新型冠状病毒肺炎产品的收入将与2024年保持一致，不包括2024年确认的约12亿美元的一次性Paxlovid收入。

The guidance accounts for an estimated $1 billion net unfavorable revenue impact due to changes under the Inflation Reduction Act (IRA), particularly Medicare Part D redesign.

由于《通货膨胀减少法案》（IRA）的变化，特别是医疗保险D部分的重新设计，该指导估计产生了10亿美元的净不利收入影响。

Also Read: Pfizer’s New Chief Scientific Officer Charts R&D Vision For High And Low-Risk Investments

另请阅读：辉瑞新任首席科学官绘制了高风险和低风险投资的研发愿景图

While IRA provisions like the $2,000 annual out-of-pocket cap are expected to benefit revenues, these are offset by eliminating the Coverage Gap Discount Program and adding manufacturer discounts in certain coverage phases.

。

The company projects operational revenue growth of flat to 5% year-over-year from the midpoint of 2024 baseline guidance, excluding non-recurring items.

该公司预计，从2024年基线指导的中点开始，运营收入同比增长将持平至5%，不包括非经常性项目。

On expenses, Pfizer anticipates full-year 2025 adjusted Selling, Informational, and Administrative expenses of $13.3 billion and $14.3 billion, while adjusted R&D expenses are expected between $10.7 billion and $11.7 billion.

在费用方面，辉瑞预计2025年全年调整后的销售、信息和管理费用分别为133亿美元和143亿美元，而调整后的研发费用预计在107亿美元至117亿美元之间。

Pfizer estimates total adjusted SI&A and R&D expenses to fall between $24.0 billion and $26.0 billion, reflecting $4.0 billion in savings from its cost realignment program by the end of 2024 and an additional $500 million in savings expected in 2025.

辉瑞（Pfizer）估计，调整后的SI＆A和研发费用总额将在240亿美元至260亿美元之间，这反映出到2024年底，其成本调整计划将节省40亿美元，预计2025年将额外节省5亿美元。

For adjusted EPS, Pfizer projects $2.80 to $3.00 in 2025, reflecting anticipated operational growth of 10% to 18% year-over-year from the midpoint of 2024 baseline guidance.

对于调整后的每股收益，辉瑞预计2025年将达到2.80美元至3.00美元，反映出从2024年基线指导的中点开始，预计运营增长率将同比增长10%至18%。

The expected improvement is attributed to higher revenues, improved operating margins driven by ongoing cost management, and the non-recurrence of one-time items that boosted 2024 adjusted EPS by approximately $0.30.

预期的改善归因于收入增加，持续成本管理推动的营业利润率提高，以及一次性项目的不复发，使2024年调整后的每股收益增加了约0.30美元。

These items included $1.2 billion in Paxlovid revenue and the removal of Haleon equity method income following the reduction of Pfizer’s ownership stake in the fourth quarter of 2024.

这些项目包括12亿美元的Paxlovid收入，以及在2024年第四季度减少辉瑞的所有权后，Haleon权益法收入的减少。

The company also reaffirmed its 2024 full-year 2024 guidance.

该公司还重申了2024年全年指导方针。

Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated: “Pfizer is in a strong position to continue making a positive impact for patients and delivering on our financial commitments in 2025.”

辉瑞董事长兼首席执行官阿尔伯特·博拉博士表示：“辉瑞处于有利地位，将继续为患者带来积极影响，并在2025年兑现我们的财务承诺。”

He added, “We also expect to continue improving our operating margins with focused financial discipline. We’ve been successful in delivering on our goal of $4 billion in net operating expense savings through 2024 from our cost realignment program, with an additional $500 million still expected to come in 2025.

他补充道：“我们还希望通过专注的财务纪律继续提高营业利润率。我们已经成功实现了通过成本调整计划到2024年净节省运营费用40亿美元的目标，预计2025年还会再节省5亿美元。

Additionally, in support of our ongoing efforts to improve gross margin performance, we will work to make additional progress with our Manufacturing Optimization Program in the coming year.”.

此外，为了支持我们不断努力提高毛利率表现，我们将在明年的制造优化计划中取得更多进展。”。

On the conference call, the company said it does not expect material U.S. policy changes regarding vaccines from the incoming administration in 2025.

在电话会议上，该公司表示，预计2025年下届政府不会对美国疫苗政策做出重大改变。

Price Action: At last check on Tuesday, PFE stock was up 2.46% to $25.87 during the premarket session.

价格行动：根据周二的最后一次检查，PFE股票在上市前交易期间上涨2.46%至25.87美元。